Bioventus (NSDQ:BVS) announced today that it chose to make a $50 million escrow payment to acquire CartiHeal and its Agili-C implant. Durham, N.C.-based Bioventus elected to make its escrow payment pursuant to its option and equity purchase agreement with CartiHeal to signal its intent to move forward with an acquisition of the company. According to […]
CartiHeal announced that it received FDA breakthrough device designation for its Agili-C implant for treating cartilage lesions. Kfar Saba, Israel.-based CartiHeal’s Agili-C implant is a proprietary implant for treating cartilage lesions in arthritic and non-arthritic joints, according to a news release. The implant is currently being observed in a pivotal investigational device exemption study comparing […]
CartiHeal said yesterday it launched an FDA investigational device exemption clinical study of its Agili-C implant for repairing cartilage, osteochondral defects and treating joint surface lesions. A total of 16 patients have been enrolled and undergone operations at European centers in the trial, the Israel-based company said. The 2-year, 250-patient pivotal study will engage US and […]
CartiHeal said today it raised $18.3 million in a new round of financing to support an FDA IDE-approved clinical trial of its Agili-C implant for use in repairing cartilage and osteochondral defects. The 2-year pivotal study will engage US and international centers and aims to show that the Israel-based company’s Agili-C is superior over the […]
E.U. biotech quartet wins $5.2M for artificial liver research
A group of European biotechnology developers won $5.2 million (€4.2 million) to advance their collaborative work on artificial liver tissue.
iRobot Corp. (NSDQ: IRBT), famous for their Roomba automated cleaning robots, invested $6 million and launched an extended partnership with InTouch Health, which develops telemedicine systems for providing remote health care.
The venture builds on an existing relationship that the companies announced last summer, under which the companies engaged in a development and licensing agreement.